These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25550572)

  • 1. Usefulness of duloxetine for Paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients.
    Otake A; Yoshino K; Ueda Y; Sawada K; Mabuchi S; Kimura T; Kobayashi E; Isobe A; Egawa-Takata T; Matsuzaki S; Fujita M; Kimura T
    Anticancer Res; 2015 Jan; 35(1):359-63. PubMed ID: 25550572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A case of Paclitaxel-induced peripheral neuropathy successfully treated with duloxetine].
    Nagashima S; Kiba T; Ogawa Y; Mura T; Kajiume S; Okada Y; Morii N; Takahashi H; Ichiba Y; Yamashiro H
    Gan To Kagaku Ryoho; 2015 May; 42(5):617-9. PubMed ID: 25981658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine Stress Axis-Dependence of Duloxetine Analgesia (Anti-Hyperalgesia) in Chemotherapy-Induced Peripheral Neuropathy.
    Staurengo-Ferrari L; Bonet IJM; Araldi D; Green PG; Levine JD
    J Neurosci; 2022 Jan; 42(3):405-415. PubMed ID: 34880120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duloxetine to prevent neuropathy in breast cancer patients under paclitaxel chemotherapy (a double-blind randomized trial).
    Aghili M; Taherioun M; Jafari F; Azadvari M; Lashkari M; Kolahdouzan K; Ghalehtaki R; Abdshah A
    Support Care Cancer; 2024 Jul; 32(8):493. PubMed ID: 38976095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy.
    Aziz MT; Good BL; Lowe DK
    Ann Pharmacother; 2014 May; 48(5):626-32. PubMed ID: 24577146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical identification of predictors for paclitaxel-induced peripheral neuropathy in patients with breast or gynaecological cancer.
    Kanbayashi Y; Hosokawa T; Kitawaki J; Taguchi T
    Anticancer Res; 2013 Mar; 33(3):1153-6. PubMed ID: 23482795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery.
    Storey DJ; Colvin LA; Mackean MJ; Mitchell R; Fleetwood-Walker SM; Fallon MT
    J Pain Symptom Manage; 2010 Jun; 39(6):e2-4. PubMed ID: 20538177
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.
    Loven D; Levavi H; Sabach G; Zart R; Andras M; Fishman A; Karmon Y; Levi T; Dabby R; Gadoth N
    Eur J Cancer Care (Engl); 2009 Jan; 18(1):78-83. PubMed ID: 19473225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy.
    Sánchez-Barroso L; Apellaniz-Ruiz M; Gutiérrez-Gutiérrez G; Santos M; Roldán-Romero JM; Curras M; Remacha L; Calsina B; Calvo I; Sereno M; Merino M; García-Donas J; Castelo B; Guerra E; Letón R; Montero-Conde C; Cascón A; Inglada-Pérez L; Robledo M; Rodríguez-Antona C
    Oncologist; 2019 Aug; 24(8):e784-e792. PubMed ID: 30470691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion].
    Noda K; Ikeda M; Kudo R; Nishiya I; Yajima A; Tanaka K; Kodama S; Takahashi T; Tokunaga A; Satoh I; Nozawa S; Taketani Y; Terashima Y; Isonishi S; Takeda Y; Nishijima M; Kuroshima Y; Fujii S; Izumi R; Tamaya T; Mori T; Okada H; Ogita S; Ozaki M; Hatae M
    Gan To Kagaku Ryoho; 1996 Feb; 23(3):317-25. PubMed ID: 8712825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity.
    Tsutsumi K; Kaname T; Shiraishi H; Kawashiri T; Egashira N
    J Pharmacol Sci; 2016 Jun; 131(2):146-9. PubMed ID: 27262900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601.
    Smith EM; Pang H; Ye C; Cirrincione C; Fleishman S; Paskett ED; Ahles T; Bressler LR; Le-Lindqwister N; Fadul CE; Loprinzi C; Shapiro CL;
    Eur J Cancer Care (Engl); 2017 Mar; 26(2):. PubMed ID: 26603828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy.
    Magnowska M; Iżycka N; Kapoła-Czyż J; Romała A; Lorek J; Spaczyński M; Nowak-Markwitz E
    Ginekol Pol; 2018; 89(4):200-4. PubMed ID: 29781075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of paclitaxel-induced peripheral neuropathy successfully treated by H2-blocker, lafutidine].
    Matsumura T; Imamura H; Kishimoto T; Miyazaki Y; Fujii C; Fujino M; Yasui Y; Anami S; Sumita R; Takada N; Fujita Y; Furukawa H
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1565-8. PubMed ID: 19755835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    J Cancer Res Clin Oncol; 2001 Jan; 127(1):55-8. PubMed ID: 11206272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.